+792.3%
HUT vs GSK
+53.4%
+738.9%
-65.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.4% | -2.7% | +9.1% | +5.5% |
| 7D | +28.3% | -4.2% | +32.4% | +26.6% |
| 30D | +12.3% | -7.5% | +19.8% | +9.9% |
| 3M | -16.8% | -3.3% | -13.5% | -17.3% |
| 6M | +111.4% | -9.3% | +120.7% | +106.8% |
| YTD | +116.6% | +1.6% | +115.0% | +121.8% |
| 1Y | +290.5% | +25.5% | +265.0% | +324.1% |
| 3Y | +792.3% | +49.3% | +743.0% | +839.0% |
| All | +792.3% | +53.4% | +738.9% | +839.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling